Share on StockTwits

DexCom (NASDAQ:DXCM) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are covering the company, Stock Ratings Network reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $39.60.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock.

Shares of DexCom (NASDAQ:DXCM) opened at 36.61 on Wednesday. DexCom has a 52 week low of $21.76 and a 52 week high of $49.83. The stock’s 50-day moving average is $37.28 and its 200-day moving average is $38.17. The company’s market cap is $2.743 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter last year, the company posted ($0.16) earnings per share. DexCom’s revenue was up 59.1% compared to the same quarter last year. Analysts expect that DexCom will post $-0.33 EPS for the current fiscal year.

In other DexCom news, Insider Jorge A. Valdes unloaded 16,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $36.66, for a total value of $586,560.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.